Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called Carboplatin with or without another study drug,
Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other
parts of the body.
The interventions involved in this study are:
- Carboplatin
- Nivolumab